Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can jeopardize their other revenue-generating business lines like M&A advisory.
Accurately determining a company’s long-term prospects isn’t easy, especially when sentiment is weak. That’s where StockStory comes in - to help you find attractive investment candidates backed by unbiased research. Keeping that in mind, here are three stocks where the skepticism is well-placed and some better opportunities to consider.
DocuSign (DOCU)
Consensus Price Target: $69.99 (0% implied return)
Creating the digital equivalent of "sign on the dotted line" for over a billion users worldwide, DocuSign (NASDAQ:DOCU) provides an agreement management platform that enables businesses to electronically prepare, sign, and manage documents and contracts.
Why Are We Bearish on DOCU?
- Average ARR growth of 5.5% over the last year has disappointed, suggesting it’s had a hard time winning long-term deals and renewals
- Demand will likely be soft over the next 12 months as Wall Street’s estimates imply tepid growth of 8.1%
- Competitive market means the company must spend more on sales and marketing to stand out even if the return on investment is low
At $70.03 per share, DocuSign trades at 3.7x forward price-to-sales. Check out our free in-depth research report to learn more about why DOCU doesn’t pass our bar.
Luxfer (LXFR)
Consensus Price Target: $18.75 (8% implied return)
With its magnesium alloys used in the construction of the famous Spirit of St. Louis aircraft, Luxfer (NYSE:LXFR) offers specialized materials, components, and gas containment devices to various industries.
Why Are We Wary of LXFR?
- Annual sales declines of 2.3% for the past two years show its products and services struggled to connect with the market during this cycle
- Projected sales growth of 2.7% for the next 12 months suggests sluggish demand
- Earnings per share have contracted by 2.1% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance
Luxfer’s stock price of $17.36 implies a valuation ratio of 13.2x forward P/E. Read our free research report to see why you should think twice about including LXFR in your portfolio.
Pediatrix Medical Group (MD)
Consensus Price Target: $26.33 (0.8% implied return)
With a network of approximately 2,620 affiliated physicians caring for some of the most vulnerable patients, Pediatrix Medical Group (NYSE:MD) provides specialized physician services focused on neonatal, maternal-fetal, pediatric cardiology and other pediatric subspecialty care across 37 states.
Why Is MD Not Exciting?
- Annual sales declines of 1.3% for the past two years show its products and services struggled to connect with the market during this cycle
- Modest revenue base of $1.95 billion gives it less fixed cost leverage and fewer distribution channels than larger companies
- Projected sales growth of 1.5% for the next 12 months suggests sluggish demand
Pediatrix Medical Group is trading at $26.14 per share, or 11x forward P/E. If you’re considering MD for your portfolio, see our FREE research report to learn more.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.